New dilemmas in small-cell lung cancer TNM clinical staging

Zarogoulidis, Konstantinos; Latsios, Dimitrios; Porpodis, Κonstantinos; Darwiche, Kaid; Antoniou, Nikolaos; Hohenforst-Schmidt, Wolfgang; Eleftheriadou, Ellada; Boutsikou, Efimia; Kontakiotis, Theodoros

doi:10.2147/ott.s44201

Cited by 17 publications

(12 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whilst, the 7 th TNM classification stratifies the patients according to the extent of the primary tumor (T-stage), lymph node involvement (N-stage) and distant metastasis (M-stage) (6)(7)(8). However, the survival of the SCLC patients in the same stage varied dramatically, previous studies showed that various clinical factors of SCLC patients were predictive factors (9)(10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

Nomogram prediction for the survival of the patients with small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

Background: Small cell lung cancer (SCLC) is a subtype of lung cancer with poor prognosis. In this study, we aimed to build a nomogram to predict the survival of individual with SCLC by incorporating significant clinical parameters. Methods:The patients with SCLC were enrolled from the First Affiliated Hospital of Guangzhou Medical University (GMUFAH) between 2009 and 2013. We identified and incorporated the independent prognostic factors to build a nomogram to predict the survival of SCLC patients. The predictive accuracy and discriminative ability of the nomogram were evaluated by concordance index (C-index) and calibration curve.We also compared the accuracy of the built model with the 7 th AJCC TNM and VALSG staging system. The nomogram was further validated in an independent cohort of 80 patients with SCLC from Cancer Center of Guangzhou Medical University (GMUCC) between 2009 and 2013.Results: A total of 275 patients with SCLC were included in the primary cohort, and seven independent prognostic factors were identified including age, N stage, metastasis status, histology, platelets to lymphocyte ratio (PLR), neuron specific enolase (NSE) and CYFRA21-1 as independent prognostic factors after using Cox regression model. A nomogram incorporating these prognostic factors was subsequently built. The calibration curves for possibilities of 1-, 2-year overall survival (OS) revealed optimal agreement between nomogram prediction and actual observation. The C-index of this nomogram was higher than that of TNM Conclusions:In this study, we established and validated a novel nomogram for the prediction of OS for the patients with SCLC. This model could provide more accurate individual prediction of survival probability of SCLC than the existing staging systems.

show abstract

Section: Introductionmentioning

confidence: 99%

Nomogram prediction for the survival of the patients with small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Şimdiye kadar akciğer kanserinin prognozunu etkileyen birçok faktör tanımlanmasına rağmen, hastalığın erken tanısı ve tedavisi prognozun temelini oluşturmaktadır (2)(3)(4). Akciğer kanseri tedavisi için güncel algoritmaların kullanılması, agresif cerrahi yöntemler, kemoterapi ve radyoterapi modalitelerinin birlikte kullanımıyla cerrahi için uygun olmayan hastalarda dahi 5 yıllık sağkalım %16'ya ulaşmıştır (5,6).…”

Section: Introductionunclassified

Lung cancer and intensive care: which patient how long?

2017

View full text Add to dashboard Cite

show abstract

“…The new cases that are estimated in the United States in 2015 were 221,200 and the deaths from lung cancer were 158,040. [1] Lung cancer may be diagnosed with symptoms or it can be found casually on chest imaging. From patients with SCLC, about 30% of them, they will have limited-stage disease (LD).…”

Section: Introductionmentioning

confidence: 99%

Small Cell Lung Cancer: Current and Future Strategies

Lampaki¹,

Lagoudi²,

Tsavlis³

et al. 2016

Oncomedicine

Self Cite

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) represents approximately 15% of all lung cancer diagnoses and over the last 20 years, in the Western world, the proportion of patients with SCLC has decreased to 13% due to world campaign for smoking cessation. Due to high growth fraction of the disease, to early dissemination with widespread metastases and also to early development of drug resistance, the treatment of SCLC remains discouraging. The median survival time without treatment is 2-4 months and with treatment the 5-year survival rate remains low at <7% overall and the most of the patients relapse within one year after first-line treatment. Chemotherapy with a platinum regimen and etoposide is the gold of standard of treatment for limited (LD) and extensive disease (ED), by adding radical thoracic radiotherapy for patients with good performance status, with LD. The new TNM classification should be used also for SCLC. For the patients who have any response is indicated the prophylactic cranial irradiation (PCI) due to high risk of brain metastases. The benefit from second-line therapy is limited and maintenance therapy did not appear to improve overall survival (OS) or progression free survival (PFS) for patients with SCLC. Many targeted agents have been investigated in LD and ED, almost all of them in unselected populations, but also with pessimistic results. Due to unchanged therapeutic options for almost four decades, is required desperately to understand better the molecular basis of SCLC and to proceed in to clinical trials for new drugs and targeted agents.

show abstract

New dilemmas in small-cell lung cancer TNM clinical staging

Cited by 17 publications

References 18 publications

Nomogram prediction for the survival of the patients with small cell lung cancer

Nomogram prediction for the survival of the patients with small cell lung cancer

Lung cancer and intensive care: which patient how long?

Small Cell Lung Cancer: Current and Future Strategies

Contact Info

Product

Resources

About